Cargando…
Phase II study of everolimus for recurrent or progressive pediatric ependymoma
BACKGROUND: Preclinical studies have suggested that mTOR pathway signaling may be a potential therapeutic target for childhood ependymoma. METHODS: A phase II clinical trial (ClinicalTrials.gov identifier: NCT02155920) of single-agent everolimus was performed to test the hypothesis that mTOR pathway...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025810/ https://www.ncbi.nlm.nih.gov/pubmed/36950217 http://dx.doi.org/10.1093/noajnl/vdad011 |